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POINT: Clinical stage IA non–small cell lung cancer determined by
computed tomography and positron emission tomography is frequently
not pathologic IA non–small cell lung cancer: The problem of
understaging
Brendon M. Stiles, MD, Elliot L. Servais, MD, Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto Paul, MD, and Nasser K. Altorki, MD
Objective: There is an increase in interest in limited resection for clinical stage IA non–small cell lung cancer.
The purpose of this study was to evaluate the accuracy of the diagnosis of clinical stage IA non–small cell lung
cancer when determined by both computed tomography and positron emission tomography scans and to deter-
mine factors associated with understaging.
Methods: A retrospective review of a prospectively maintained database of patients with non–small cell lung
cancer was performed. Patients with clinical stage IA cancer determined by preoperative computed tomogra-
phy and positron emission tomography scan were reviewed. The influence of the following factors was analyzed
with regard to accuracy of clinical staging: tumor size, location, histology, and positron emission tomography
positivity.
Results: Of the 266 patients identified, cancer was correctly staged in 65%. Final pathologic stages also included
IB (15%), IIA (2.6%), IIB (4.1%), IIIA (4.9%), IIIB (7.5%), and IV (.08%). Positive lymph nodes were found
in 11.7% of patients. Pathologic T classification changed in 28.2% of patients. Cancer in patients with clinical
tumor size greater than 2 cm (n¼ 68) was significantly more likely to be understaged than in patients with tumors
2 cm or less (49% vs 29%, P¼ .003). Cancer in patients with a positron emission tomography-positive (positron
emission tomographyþVE) primary evaluation (n ¼ 218) was also more likely to be understaged (39% vs 15%,
P ¼ .001). Of patients with positron emission tomographyþVE tumors greater than 2 cm, cancer was clinically
understaged in 55%, compared with 32% for positron emission tomographyþVE tumors 2 cm or less, and only
17% for positron emission tomography negative (VE) tumors less than 2 cm.
Conclusion: Clinical stage IA lung cancer is frequently understaged in patients. Size greater than 2 cm and pos-
itron emission tomography positivity are risk factors for understaging. Limited resection should be undertaken
with caution in such patients.
POINT/COUNTERPOINTCurrent treatment strategies for non–small cell lung cancer
(NSCLC) depend on the accuracy of clinical staging. Al-
though the pathologic stage in the TNM classification
more accurately predicts outcomes in patients with
NSCLC,1 treatment plans are by necessity guided by clinical
staging in the TNM classification. The primary objective of
preoperative staging is to rule out metastatic or locally ad-
vanced disease at presentation. Clinical staging has histori-
cally relied on computed tomography (CT) and cervical
mediastinoscopy. More recently, positron emission tomog-
raphy (PET) has become an important noninvasive tool in
mediastinal staging.2-7
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clinical and pathologic staging, even in stage I disease. A
prospective trial to evaluate molecular markers of microme-
tastatic disease, Cancer and Leukemia Group B (CALGB)
9761, also evaluated the correspondence between clinical
and pathologic staging in stage I (T1–2, N0) NSCLC.8
All patients had CT scans, but only a minority (12.2%)
had PET scans. Of patients ultimately found to have
NSCLC, only 71.6% had pathologically documented stage
I disease. Previous studies have suggested that the addition
of PET to CT improves the accuracy of clinical staging
across all stages of lung cancer.9-11 However, a prospective
trial failed to show a significant improvement in accuracy
of clinical staging in the subgroup of patients with stage
I: 68% for integrated PET/CT versus 66% for CT alone.12
Given the critical importance of clinical staging in deter-
mining further diagnostic and treatment algorithms, it is
paramount to critically review current clinical staging
techniques and to determine factors associated with under-
staging.
PATIENTS AND METHODS
The Thoracic Surgery Tumor Registry at New York Presbyterian Hospi-
tal, Weill Medical College of Cornell University, served as the database.Cardiovascular Surgery c Volume 137, Number 1 13
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CALGB ¼ Cancer and Leukemia Group B
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
SUV ¼ standardized uptake value
VPI ¼ visceral pleural invasion
A retrospective review of this prospective tumor database identified all pa-
tients with pathologically proven NSCLC who were deemed clinically to
have stage IA disease, operated on between January 2000 and September
2007. The study included only patients in whom clinical stage IA disease
was determined by both CT and PET scan (International Union Against
Cancer/American Joint Committee on Cancer staging scheme). Clinical
IA stage was determined from a combination of CT scan (including some
with contrast and some without) and PET scan findings. If lymph nodes
had a maximum standardized uptake value (SUV) of less than 2.0 g/mL
or were read as ‘‘no uptake,’’ they were deemed to be negative, even if
greater than 1 cm by CT scan. Approval for review of hospital records
was obtained from the institutional review board, waiving the need for
informed consent. Data analyzed included patient age and gender, preoper-
ative radiologic assessments, and tumor location (lobe; central or peripheral)
and histology. Tumor size was recorded as the maximum dimension deter-
mined from the preoperative CT scan. A tumor was considered peripheral if
the center of the tumor was located within the outer one third of the lung
field as determined from the radial distance from the hilum to the lung pe-
riphery. Surgical data were also reviewed, including the use of mediastino-
scopy, extent of surgical resection, and number and stations of lymph nodes
resected. Tumor size determined at pathologic review, pathologic nodal
classification, and pathologic stage were recorded. Follow-up was obtained
through routine office visits or via telephone contact. All patients were fol-
lowed through September 2007. Statistical analysis was performed using
SPSS statistical software (SPSS Inc, Chicago, Ill). Survival was calculated
using the Kaplan–Meier method. Categoric data in cross-tabulation tables
were compared using Fisher’s exact test or Pearson’s chi-square test. The
independent effect of clinically relevant variables on staging accuracy
was evaluated using a logistic regression model.
RESULTS
Clinical Findings
From January 2000 to September 2007, 561 patients with
cIA NSCLC underwent surgical resection. Of these 561 pa-
tients, 295 did not have PET scans preoperatively. The re-
maining 266 patients (37.2% were men, 62.8% were
women) who had both CT and PET scans for clinical staging
served as the basis of the study (Table 1). Their median age
was 70 years (range 43–90 years). Mediastinoscopy was per-
formed in 28.2% (n¼ 75) of patients. No patient had a pos-
itive mediastinoscopy. Anatomic resection was performed in
92.9% of patients, with 87.6% undergoing lobectomy. Of
patients undergoing lobectomy, 45% underwent video-
assisted thoracic surgery lobectomies. The right upper lobe
(36.2%) and left upper lobe (28%) were the most common
lobes resected.14 The Journal of Thoracic and Cardiovascular SurPathologic Findings
A median number of 12 lymph nodes were identified in
the pathologic specimens. Approximately two thirds
(65.4%) of patients with clinical stage IA had pathologic
stage IA. Final pathologic stages also included IB (n ¼ 40,
15.0%), IIA (n ¼ 7, 2.6%), IIB (n ¼ 10, 3.8%), IIIA
(n ¼ 13, 4.9%), IIIB (n ¼ 20, 7.5%), and IV (n ¼ 2,
0.75%). Thus, cancer was upstaged to stage II to IV in 52
patients (19.5%). Lobar location of the primary tumor had
no effect on accuracy of clinical staging. The majority of pa-
tients (79.3%) had adenocarcinoma or adenocarcinoma with
bronchioloalveolar features. Histology also had no statisti-
cally significant effect on accuracy of staging.
TNM Correlation
Pathologic T-stage changed in 28.2% of patients (Table 2).
T-stage was upstaged pathologically to T2 in 52 patients
(19.5%), of whom 42 (15.8%) had pleural invasion and 10
(3.8%) had tumor size greater than 3 cm. Twenty patients
(7.5%) were noted to have stage T4 on final pathologic
review, all for satellite nodules within the resected lobe.
Cancer was upstaged to T3 in an additional 2 patients
(0.8%). In regard to pathologic nodal evaluation, 31
patients (11.7%) were noted to have metastatic cancer
in their lymph nodes. Of the total cohort, 6.8% had N1
disease and 4.9% had N2 disease. Of the 13 patients
TABLE 1. Patient characteristics (N ¼ 266)
Median age (range) 70 y (43–90 y)
Gender
Male 99 (37%)
Female 167 (63%)
Operation
Wedge 19 (7%)
Segmentectomy 10 (4%)
Lobectomy 233 (88%)
VATS lobectomy 105 (45% of lobectomies)
Bilobectomy 3 (1%)
Pneumonectomy 1 (4%)
Median lymph nodes 12
Histology
Adenocarcinoma 88 (33%)
Adenocarcinoma with BAC 123 (46%)
BAC 11 (4%)
Squamous 24 (9%)
Other 20 (8%)
Pathologic stage
IA 174 (65%)
IB 40 (15%)
IIA 7 (3%)
IIB 10 (4%)
IIIA 13 (5%)
IIIB 20 (8%)
IV 2 (1%)
VATS, Video-assisted thoracic surgery; BAC, bronchioloalveolar carcinoma.gery c January 2009
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des at station 5 or 6, 4 had nodes at station 2 or 4, and 1 had
nodes at station 9 (3 had multilevel disease). Cancer was
pathologically upstaged for both T and N criteria in 14 pa-
tients (5.3%). Two patients were noted to have an ipsilat-
eral nodule of identical histology in a different lobe from
the primary tumor and were therefore judged to have M1.
Multivariate Analysis
The following factors were analyzed with respect to pre-
dicting the accuracy of clinical staging: patient gender, tu-
mor histology, CT size (2 cm vs>2 cm), tumor location
(central vs peripheral), and PET result (Table 3). Patients
were categorized with pIA versus all other pathologic stages.
Of the listed clinical factors, CT size and PET status were
found to be statistically significant. The estimated hazard ra-
tio of pathologic upstaging for tumors greater than 2 cm
compared with tumors 2 cm or less was 2.43, with a 95%
confidence interval of 1.24 to 4.77 (P ¼ .01). Similarly,
the hazard ratio was 3.63 for PETþVE tumors compared
with PET –VE tumors, with a 95% confidence interval of
1.33 to 9.90 (P ¼ .01).
TABLE 3. Predictors of pathologic upstaging
Variables Hazard ratio 95% CI P value
Gender
Female 1.000
Male 1.657 0.878–3.130 .119
Histology
Adenocarcinoma 1.000
No adenocarcinoma 0.675 0.286–1.592 .369
Location
Central 1.000
Peripheral 0.830 0.386–1.781 .632
PET result
Negative 1.000
Positive 3.626 1.329–9.896 .012
Clinical tumor size
0–2 cm 1.000
>2 cm 2.431 1.240–4.766 .010
CI, Confidence interval; PET, positron emission tomography.
TABLE 2. Pathologic TNM classification of patients
T stage
T1 192 (72.2%)
T2 52 (19.5%)
T3 2 (0.8%)
T4 20 (7.5%)
N stage
N0 235 (88.3%)
N1 18 (6.8%)
N2 13 (4.9%)
M stage
M0 264 (99.2%)
M1 2 (0.8%)The Journal of Thoracic andEffect of Tumor Size
Patients were divided into 2 groups for analysis on the ba-
sis of tumor size on preoperative CT scan: those with tumors
less than or equal to 2 cm (n ¼ 181) and those with tumors
greater than 2 cm (n ¼ 68). Exact preoperative tumor size
measurement was not recorded or available in 17 patients.
Clinical stage was accurate in 71.3% of patients with the
smaller tumors compared with only 51.5% in patients with
tumors greater than 2 cm (P¼ .003). Final pathologic stages
are listed in Table 1. The most common upstaging was to
pIB. Of patients with tumors 2 cm or less, 16.6% were ulti-
mately found to have stage II to IV disease, compared with
29.5% of patients with tumors greater than 2 cm (P ¼ .02).
Effect of Positron Emission Tomography Positivity
We next analyzed the effect of PET scans on the accuracy
of clinical staging (Table 4). Cancer was correctly clinical
staged as IA in slightly more than 60% of patients with pos-
itive PET scans (n ¼ 218). Cancer in patients with negative
PET scans (n ¼ 48) was significantly more likely to be cor-
rectly staged pathologically as IA (P ¼ .001), with an accu-
racy of 85.4%. Cancer that was upstaged in the majority of
patients with PETþVE tumors was reclassified as pIB (n ¼
39, 17.9%). However, cancer in 21.5% of patients was up-
staged to pII-IV disease, compared with only 12.5% for
patients with PET VE tumors (not significant). Among
patients with PETþVE, 194 had an SUVmax recorded. Of
those who were found to have pIA, the median SUVmax
was 2.9 g/mL versus 4.5 g/mL for the group that was up-
staged to higher pathologic stages (P ¼ .01). The median
SUVmax for the whole PET þVE group was 3.4 g/mL.
When patients were divided into groups of low SUV (<3.4
g/mL) or high SUV (3.4 g/mL), differences in staging ac-
curacy were appreciated. Of the low SUV group, 72% were
accurately staged as IA, compared with only 54% of the
high SUV group (P ¼ .008, c2). Upstaging to pII-IV oc-
curred in 14.4% of the low SUV group compared with
23.8% of the high SUV group (not significant).
Combined Effect of Tumor Size and Positron
Emission Tomography Status
We next analyzed 4 separate groups of patients according
to size and PET criteria: PETþVE tumors greater than 2 cm;
PETþVE tumors 2 cm or less; PETVE tumors greater than
2 cm; and PETVE tumors 2 cm or less (Table 5). Of those
patients with PETþVE tumors greater than 2 cm (n ¼ 60),
cancer was correctly clinically staged in only 45%. Of those
patients with PETþVE tumors 2 cm or less (n ¼ 141), can-
cer was accurately staged as IA 68.1% of the time. This dif-
ference was statistically significant (P ¼ .002). As noted
previously, cancer in patients with PET VE was more
accurately staged. Cancer was correctly staged 100% of
the time in those with PETVE tumors greater than 2 cmCardiovascular Surgery c Volume 137, Number 1 15
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IA IB IIA IIB IIIA IIIB IV
Size (n ¼ 249*) 2 cm (n ¼ 181) 71% 12% 1.7% 3.9% 4.4% 3.9% 0
>2 cm (n ¼ 68) 51% 19% 5.9% 5.9% 5.9% 10% 1.5%
PET (n ¼ 266) Negative (n ¼ 48) 85% 2.1% 0 2.1% 2.1% 8.3% 0
Positive (n ¼ 218) 61% 18% 3.2% 4.6% 5.5% 7.3% 0.9%
PET, Positron emission tomography. *Exact preoperative tumor size was not recorded in 17 patients.(n ¼ 8), whereas cancer was correctly staged 82.5% of the
time in those with PETVE tumors 2 cm or less (n ¼ 40).
Effect of Tumor Location
Tumor location, central versus peripheral, was deter-
mined in 228 patients (86%). In 38 patients, CT and PET
scans were unavailable for review. No definitive determina-
tion could be made on the basis of review of radiologic, sur-
gical, and pathologic records in these patients. Among the
remaining 228 patients, 181 (79%) had peripheral tumors
and 47 (21%) had central tumors. No significant difference
was noted between the accuracy of cIA staging: 71% for pe-
ripheral tumors versus 66% for central tumors. When com-
bining location with PET status, cancer in patients with
peripheral PET –VE (n ¼ 37) was correctly staged 92%
of the time, compared with 65% for patients with peripheral
PETþVE (n ¼ 144), 71% for patients with central PET–V
(n ¼ 7), and 65% for patients with central PETþVE (n ¼
40). This difference was statistically significant (P ¼
.015). Similarly, when combining tumor location with tumor
size, differences were noted (P¼ .033). Peripheral tumors 2
cm or less (n ¼ 129) were correctly staged 77% of the time
compared with 55% for peripheral tumors greater than 2 cm
(n ¼ 42), 71% for central tumors 2 cm or less (n ¼ 31), and
55% for central tumors greater than 2 cm (n ¼ 11). The dif-
ference between the first 2 groups was significant (P ¼ .01).
Peripheral Positron Emission Tomography-Positive
Tumors 2 Centimeters or Less
When evaluating the 3 clinical factors of location, size,
and PET status, the most common subgroup of patients in-
cluded those with peripheral PETþVE tumors 2 cm or less
(n¼ 97, 36% of total). Of these, cancer was correctly staged
as IA in 72%. Cancer was upstaged to pIB in 13%. Eleven
(11%) of these patients had nodal metastases, 6 with N1 dis-
ease and 5 with N2 disease. Among the patients with N1 dis-
ease, 5 had positive lobar nodes (station 11 or 12) only, and 1
also had a positive station 10 node. For the patients with N2
disease, 3 had positive station 7 lymph nodes, 1 had a posi-
tive station 4 lymph node, and 1 had a positive level 5 lymph
node.
Survival
With a median follow-up for surviving patients of 24.3
months, the cohort had a 92.4% 5-year probability of overall16 The Journal of Thoracic and Cardiovascular Sursurvival. As demonstrated in Figure 1, patients found to have
pIA disease (n ¼ 174) were significantly more likely to be
alive at 5 years than were patients with pathologically up-
staged cancer (n ¼ 92; 99.4% vs 79.7%; P< .001, log-
rank). There was no significant difference in overall 5-year
survival between patients with pIA and pIB disease
(99.4% vs 96.4%).
DISCUSSION
The clinical staging of patients with NSCLC guides
patient care and clinical research. A previous report
from a prospective, multi-institutional trial demonstrated
a poor predictive value of clinical staging systems in
stage I NSCLC.8 Of patients found to have NSCLC
who were enrolled in CALGB 9761, clinical staging
was accurate in only 71.6% of those thought to have
stage I disease. Other retrospective studies reported simi-
lar rates of inaccurate staging for early-stage NSCLC.13,14
Notably, only a minority of patients in these studies had
PET scans, 12.2% in the CALGB 9761 study. PET scans
are thought to improve the accuracy of mediastinal stag-
ing and diagnosing distant metastatic disease in patients
with lung cancer.9-11 It is unclear, however, whether
PET scan improves the staging accuracy of patients
with early-stage NSCLC. One previous study compared
staging with CT versus staging with a combination of
CT and integrated PET/CT across all clinical stages.
Among patients with clinical stage I disease in that study,
accuracies were only 66% and 68% for CT and CT/PET,
respectively.12
Given the critical importance of clinical staging in deter-
mining diagnostic and treatment algorithms, we reviewed
the accuracy of our own staging of patients with clinical
IA NSCLC using the combination of CT and PET scans. Al-
though these patients are uniformly treated surgically, there
are likely distinct groups of patients within the population as
a whole. This is supported by the fact that the 5-year survival
among patients with cIA is only 61% as reported in the 1997
TABLE 5. Accuracy of clinical staging for subgroups of patients with
cIA
PETþVE,>2 cm (n ¼ 60) 45%
PETþVE, 2 cm (n ¼ 141) 68%
PETVE,>2 cm (n ¼ 8) 100%
PETVE, 2 cm (n ¼ 40) 83%
PET, Positron emission tomography.gery c January 2009
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Cancer.1
In our study of 266 patients with cIA NSCLC, we found
only a 65.4% accuracy of predicting pIA. This is similar to
previous surgical series.8,12-14 The majority of patients with
changed stages (43%) had an upstage only to pIB. These pa-
tients predominantly had visceral pleural invasion (VPI) by
their tumors, with their T stage changing from cT1 to pT2.
There have been conflicting reports on the prognostic impor-
tance of VPI. VPI likely predicts pleural dissemination of
cancer cells and N2 involvement.15-18 However, others
have shown that VPI does not influence survival in those
with tumors less than 3 cm in size.19 Previous staging system
revisions demonstrated that patients with pIB disease have
worsened survival compared with patients with pIA disease:
57% versus 67% at 5 years.1 Recent proposals for the revi-
sion of T descriptors focus on tumor size cutpoints but do not
address VPI.20 However, despite potential differences in sur-
vival, the treatment algorithm of our patients with stage IB
would not have changed even if their disease were correctly
staged clinically.
Treatment algorithms may differ in patients with higher
stage disease. In the current study, cancer was upstaged to
pII-IV in 19.5% of patients. Without routine PET scans in
CALGB 9761, 28.4% of patients were upstaged to pII-
IV.8 Of our total population of patients whose disease was
staged with CT and PET scans, 11.7% were noted to have
metastatic lymph nodes, 6.8% with N1 disease and 4.9%
with N2 disease. This is similar to the reported rate of missed
N2 disease in previous reports.21,22 Of the whole cohort,
7.5% of patients were found to have satellite tumor nodules
within the lobe of the lung resected and were therefore up-
staged to pT4, pIIIB. Because most patients with N1 disease
FIGURE 1. Overall survival based on final pathologic stage.The Journal of Thoracic andor T4 disease secondary to satellite nodules typically un-
dergo primary surgical resection, the initial treatment algo-
rithm would have likely only changed in 5.6% of patients,
those with N2 or metastatic disease. Despite the fact that me-
diastinoscopy was performed in 28% of the total patient
population and in 23% of patients ultimately found to
have N2 disease, mediastinoscopy did not reveal metastatic
nodal disease in any of these patients. We have previously
reported the important role of mediastinoscopy in further
staging clinical stage I (A and B) in patients, particularly
in larger tumors, centrally located tumors, and primary tu-
mors with an SUVmax 4 g/mL or more. Our current report
suggests that the recommendation for mediastinoscopy
may be less stringent for patients with cIA. Meyers and col-
leagues23 have suggested that routine mediastinoscopy is not
cost-effective when patients have already been screened
with CT and PET. However, we still favor routine mediasti-
noscopy in large or central tumors, particularly when associ-
ated with PET positivity.
Given that cancer in patients with cIA NSCLC was under-
staged approximately one third of the time, we sought to de-
termine factors associated with understaging. Tumor size
has previously been demonstrated to be a determinant of
stage distribution in T1 NSCLC.24 Tumors greater than
2.0 cm are more likely to metastasize to lymph nodes
when compared with tumors 2.0 cm or less. A survival dif-
ference is also apparent at this size cutpoint. Data from the
International Association for the Study of Lung Cancer
Lung Cancer Staging Project showed 5-year survivals of
77% for the smaller tumors and 71% for the larger tumors.20
For this reason, the Staging Committee recommended
changing the T classification to subclassify T1 into T1a
(2.0 cm) and T1b (>2.0 cm). We therefore examined the
accuracy of clinical staging on the basis of CT size of the pri-
mary tumor. It is not surprising that staging accuracy was
significantly better for the smaller tumors: 71.3% versus
51.5%. Cancer was upstaged to pII-IV in approximately
one third (29.5%) of patients with tumors greater than 2 cm.
PET positivity has also been identified as a risk factor for
occult mediastinal metastases, recurrence, and death in stage
I NSCLC.21,22,25,26 We have previously demonstrated that in
patients with a PETVE mediastinum, those with occult N2
metastases had a higher median SUVmax of the primary tu-
mor than did patients without N2 disease.21 In the current
study, we demonstrated that cancer in patients with PET
þVE was accurately staged only 60.6% of the time, com-
pared with 85.4% accuracy in patients with PETVE scans.
In particular, cancer in patients with a higher SUVmax (3.4
g/mL) was likely to be understaged. Only 54% of these pa-
tients had pIA. This is in accordance with previous reports in
which high SUVmax predicted upstaging and poor survival
in patients with stage I.21,22,25,26
These findings could have a significant effect on the inter-
pretation of studies involving the treatment of stage IACardiovascular Surgery c Volume 137, Number 1 17
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tion therapy has been demonstrated to be efficacious in pa-
tients with medically inoperable disease.27 The use of
stereotactic body radiation therapy is now being extended
to patients who are medically suitable for surgical anatomic
resection (Radiation Therapy Oncology Group 0618). Re-
sults of this trial and similar trials without a resectional com-
ponent will be heavily dependent on the accuracy of clinical
staging. Similarly, investigations of neoadjuvant chemother-
apy and biological therapy continue in early-stage NSCLC.
Accurate clinical staging is of paramount importance in as-
sessing the results of these investigational trials.
Clinical staging will also certainly affect surgical deci-
sion-making. In particular, there has been resurgent interest
in limited resection for early-stage lung cancer. Since the
findings from the Lung Cancer Study Group of a 3-fold in-
crease in local recurrence in patients who had sublobar re-
section, lobectomy has remained the preferential treatment
for NSCLC in most centers.28 However several groups, par-
ticularly in Japan, have since reported good results with sub-
lobar resection for stage I NSCLC.29-31 The mode of
resection did not affect disease-free survival. Locoregional
recurrence was low. However, these studies were limited
to patients with T1. The efficacy of sublobar resection is
not well established for larger tumors or for those with
VPI. In a recent retrospective review of sublobar resection
for patients with stage I NSCLC, El-Sherif and colleagues32
demonstrated a lower survival with sublobar resection
among the subpopulation with stage IB disease: 50% versus
58% for lobectomy. There was an increased incidence of
VPI in the group of patients undergoing sublobar resection
(76% vs 37%).
CONCLUSIONS
CALGB140503, a prospective, randomized study of lo-
bectomy versus sublobar resection for small peripheral
NSCLC, has begun to accrue patients in the United States.
This trial excludes patients with tumors greater than 2 cm.
We expect that the majority of patients entered in this trial
will resemble the most common subgroup in the current
study: those with peripheral PET þVE tumors 2 cm or
less. The accuracy of clinical staging in this group of pa-
tients was 72%. Intraoperative confirmation of N0 status
by sampling station 4, 7, 5, or 6, and 10 lymph nodes
would have excluded all of those patients ultimately found
to have N2 disease. CALGB140503 will provide further
data on the efficacy of lesser resections for cIA NSCLC
and should provide further multicenter, prospective data
on the accuracy of clinical staging. Until such questions
are resolved, limited resection should be undertaken with
caution in patients with cIA NSCLC. Certain subgroups
demand special consideration. When combining the 2 fac-
tors of tumor size greater than 2 cm and positive PET18 The Journal of Thoracic and Cardiovascular Surstatus, only 45% of patients with clinical stage IA retained
that pathologic stage. These factors should be taken into
consideration before including this group of patients in
clinical trials.
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